This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early
While melanoma is one of the most aggressive cancers, making early detection crucial for outcomes, because it is visible on the surface, there are opportunities to catch it early, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Teledermatology Can Increase Access for Patients With High-Risk Melanoma: Erik Jaklitsch
Dermatology lends itself well to telemedicine, particularly as a screening tool to reduce wait times and increase access to care for patients with high-risk melanoma, said Erik Jaklitsch, second-year medical student at the University of Pittsburgh.
Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says
A panel assembled at the American Academy of Dermatology 2023 Annual Meeting encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
Patients With AD Have More Options With Biologics, JAK Inhibitors, Says Dr Emma Guttman-Yassky
With both biologics and Janus kinase (JAK) inhibitors available to treat atopic dermatitis, providers have more options for patients, said Emma Guttman-Yassky, MD, PhD, FAAD, of Mount Sinai.
Investigators Highlight Disparities Evident in Skin Disease Care, Data Collection
Posters presented at the American Academy of Dermatology 2023 Annual Meeting provided a snapshot of disparities in dermatology care, both in terms of geographic differences in access to care and collection of race/ethnicity data in clinical trials.
Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability
A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.
Drs Dellavalle and Rodriguez Discuss Disparities in Prescription Patterns for Atopic Dermatitis
Using the DataDerm database has uncovered disparities in prescription patterns, but it’s still early in the process of understanding why those disparities might exist, said Robert Dellavalle, MD, PhD, MSPH, and Ramiro Rodriguez, MD, both of University of Colorado School of Medicine.
Dr Haley Naik Discusses Using Biologics and the Drug Pipeline for Hidradenitis Suppurativa
There are certain considerations when choosing which patient is the best fit for a biologic to treat hidradenitis suppurativa, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
How Our Understanding of Inflammatory Skin Disease Has Evolved From the 4 Humors to Targeted Therapies
Once thought of as the result of an imbalance in bodily humors, inflammatory skin diseases are now understood to arise from types of immune responses, opening the door to targeted therapies and personalized medicine, according to speakers at the American Academy of Dermatology 2023 Annual Meeting.
Examining Dermatological Care for Transgender Patients
Treatable skin diseases in the transgender population can be overlooked and not managed, despite how they can negatively impact quality of life, according to researchers.
Late-Breaking Abstracts Demonstrate Value of Persistence With Ruxolitinib Cream for Vitiligo
Amid a packed roster of of late-breaking research at the American Academy of Dermatology 2023 Annual Meeting, investigators presented findings from long-term extensions of the Topical Ruxolitinib Evaluation in Vitiligo phase 3 studies.
Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo
Similar to other therapies, approximately 40% of patients with vitiligo who stopped treatment with ruxolitinib cream relapsed, but they achieved repigmentation once treatment was reinitiated, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care
Speakers at the American Academy of Dermatology 2023 Annual Meeting highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.
Dr Monica Li Highlights Advances in Microneedling
At the American Academy of Dermatology annual meeting there will be multiple presentations on hot topics and the latest advances in microneedling, explained Monica Li, MD, clinical instructor, Department of Dermatology and Skin Science, University of British Columbia.
Experts Herald “Year of the JAK Inhibitor” in Dermatology
A symposium at the American Academy of Dermatology 2023 Annual Meeting convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic dermatitis and vitiligo.
Dermatologists’ Focus to Delve Below the Skin at Annual Conference
The 2023 American Academy of Dermatology Annual Meeting, held in New Orleans, Louisiana, from March 17-21, 2023, will feature research and presentations exploring the mechanisms, presentation, and treatment of dermatological disorders.
Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting
There is a lot to talk about in the vitiligo space at this year’s annual meeting of the American Academy of Dermatology (AAD), said John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Panel Addresses Therapeutic, Risk Stratification Considerations for Advanced Nonmelanoma Skin Cancers
A Monday session at the 2022 American Academy of Dermatology Annual Meeting discussed strategies for risk stratification and therapeutic management of nonmelanoma skin cancers.
Jonathan Kentley Discusses Applications of AI in Dermatology
Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, explains ways artificial intelligence (AI) is being used in dermatology, including smartphone applications, at the 2022 American Academy of Dermatology Annual Meeting.
Dr Bernice Kwong on GVHD: Empower Patients to Call on Doctors for Help
Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of Dermatology Annual Meeting, emphasizing the importance of the relationship between patients and doctors.
Underscoring the Diversity Issue in Dermatology: Clinical Trials, Therapeutics, and Care Management
Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Precision Medicine Considerations in Melanoma: Identifying Patients and Optimizing Genetic, Molecular Testing
Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Dr David Rosmarin on Tailored Biologic Treatments, New Vitiligo Research
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Dr Robert Sidbury Summarizes Updated Atopic Dermatitis Guidelines at AAD 2022
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.
Panel Reviews Dietary Triggers, Best Practices for Management of Dermatologic Diseases
A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.
Ruxolitinib Cream Shows Improved Efficacy, Sustained Safety in Vitiligo After Extended Follow-up
Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.
Delving Into Clinical, Epidemiological Differences of Adult, Pediatric Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.
Dr Alan Menter Discusses 2022 Psoriasis Guideline Updates
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Dr Art Papier on How Project IMPACT Aims to Reduce Racial Disparities in Dermatology
The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.
AAD 2022 to Address Diversity, Health Equity, and Emerging Therapeutics
Emerging research on therapeutics and practical approaches to managing a myriad of dermatological conditions, as well as a growing focus on diversity, equity, and inclusion will be explored at the 2022 American Academy of Dermatology (AAD) Annual Meeting, which will take place March 25-29, in Boston, Massachusetts.
2 Clarke Drive Cranbury, NJ 08512